Arch Biopartners Advances Phase II AKI Trial
TORONTO, May 22, 2026 Arch Biopartners announced that Royal Columbian Hospital (RCH) in British Columbia has dosed its first...
Alzheimer’s Disease ASCO 2026 Autoimmune Disease Bio-Pharma biologics biopharma biopharma innovation Biotechnology Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development FDA fda approval FDA clearance GCP Gene Therapy Healthcare Innovation Immuno-Oncology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody NSCLC Oncology oncology innovation oncology research Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 trial Precision Medicine Precision Oncology rare disease rare diseases Regenerative Medicine regulatory compliance targeted therapy
TORONTO, May 22, 2026 Arch Biopartners announced that Royal Columbian Hospital (RCH) in British Columbia has dosed its first...
SOUTHLAKE, TEXAS, April 30, 2026 Renibus Therapeutics has announced the oral presentation of Phase 3 PROTECT trial data for...
February 24, 2026 – Cincinnati, Ohio & Tacoma, Washington, USA Cincinnati Children’s Hospital Medical Center has announced a strategic...
TUCSON, Ariz., Feb. 12, 2026 — Picard Medical, parent company of SynCardia Systems, announced a landmark bridge-to-transplant milestone at...
TORONTO, November 5, 2025 — Arch Biopartners Inc. (TSXV: ARCH, OTCQB: ACHFF) announced that the Fraser Health Research Ethics...
